Abstract
BackgroundRespiratory syncytial virus (RSV) is the leading cause of bronchiolitis in infants. Palivizumab is an anti-RSV monoclonal antibody providing passive immunity against RSV. The Joint Committee for Vaccination and Immunisation...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Archives of Disease in Childhood - Fetal and Neonatal Edition
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
